Article

Targeting oncogenic K-Ras mutants with a small-molecule degrader through Nedd4-1

2024-04-29

Abstract excerpt

K-Ras mutations represent a most prevalent oncogenic alteration in human cancers. Despite of tremendous efforts, it remains a big challenge to develop inhibitors that can target the oncogenic K-Ras mutants, especially mutants without specific active or charged side chains such as K-Ras G12V . Here, taking advantage of our previous finding that Nedd4-1 is a bona fide E3 ubiquitin ligase for wild-type Ras proteins,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a4259622-b48a-5517-b196-dd280f55c036
DOI: 10.1101/2024.04.26.591418

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting oncogenic K-Ras mutants with a small-molecule degrader through Nedd4-1DOI 10.1101/2024.04.26.591418Read

Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles.Semantic proximity Read

Impeded Nedd4-1-Mediated Ras Degradation Underlies Ras-Driven TumorigenesisSemantic proximity Read

Targeting endogenous K-RAS for degradation through the affinity-directed protein missile systemSemantic proximity Read

MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapySemantic proximity Read

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.Semantic proximity Read

bioPROTACs establish RAS as a degradable target and provide novel RAS biology insightsSemantic proximity Read

Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors.Semantic proximity Read

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC.Semantic proximity Read

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read

Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and ClinicalSemantic proximity Read

Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system.Semantic proximity Read

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.Semantic proximity Read